Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation

Ifeoma I Ulasi1, Ejikeme B Arodiwe, Chinwuba K Ijoma

  • 1Renal Unit, Department of Medicine, College of Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria. ifeomaulasi@yahoo.co.uk

Ethnicity & Disease
|October 26, 2006
PubMed

Insights

Left ventricular hypertrophy (LVH) affects nearly all patients with chronic kidney disease (CKD) in Nigeria. Mean arterial pressure and hemoglobin levels are key predictors of LVH in these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Public Health

Background:

  • Chronic kidney disease (CKD) significantly increases cardiovascular risks, with left ventricular hypertrophy (LVH) being a primary complication due to volume and pressure overload.
  • Information on CKD complications, particularly LVH, in African Black populations is limited.
  • This study addresses the knowledge gap by evaluating LVH prevalence and associated factors in pre-dialysis CKD patients in Nigeria.

Purpose of the Study:

  • To determine the prevalence of left ventricular hypertrophy (LVH) in pre-dialysis patients with chronic kidney disease (CKD).
  • To identify factors associated with LVH in this patient population using echocardiography.
  • To provide insights into CKD management and cardiovascular risk in a developing country context.

Main Methods:

  • Eighty-eight pre-dialysis CKD patients and 45 age- and sex-matched controls were enrolled at University of Nigeria Teaching Hospital.
  • Clinical, laboratory, and echocardiographic parameters were measured.
  • Multiple linear regression analysis was used to identify predictors of LVH.

Main Results:

  • LVH was highly prevalent, found in 95.5% of CKD patients versus 6.7% of controls.
  • Eccentric hypertrophy (54.6%) was more common than concentric hypertrophy (40.9%).
  • Significant predictors of LVH included mean arterial pressure (32%), hemoglobin concentration (22%), male sex (17%), and creatinine clearance (24%).
  • Hypertension was present in 85.2% of patients, with advanced CKD (stage 4 or 5).

Conclusions:

  • A strong association exists between CKD and LVH, even at initial nephrologist evaluation in developing countries.
  • High LVH prevalence, anemia, and severe hypertension are common at first presentation in CKD patients.
  • Aggressive primary prevention and early detection/treatment of CKD causes are crucial to mitigate complications like LVH.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...